ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a large decline in short interest in October. As of October 31st, there was short interest totalling 24,000 shares, a decline of 96.7% from the October 15th total of 717,700 shares. Currently, 4.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 316,200 shares, the short-interest ratio is currently 0.1 days.

ENDRA Life Sciences Stock Performance

ENDRA Life Sciences stock remained flat at $6.05 during midday trading on Tuesday. The company’s stock had a trading volume of 141,337 shares, compared to its average volume of 98,173. The firm has a market cap of $2.97 million, a PE ratio of 0.00 and a beta of 0.74. ENDRA Life Sciences has a 1 year low of $5.23 and a 1 year high of $4,882.50. The firm’s 50 day moving average is $8.27 and its 200-day moving average is $7,669.60.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($140.00) EPS for the quarter, missing analysts’ consensus estimates of ($122.50) by ($17.50). Research analysts anticipate that ENDRA Life Sciences will post -387.41 EPS for the current fiscal year.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.